Dose adjustment of direct oral anticoagulants (DOACs) is not required in the setting of acute
PE treatment according to the manufacturer's labelling, beyond the contraindication in …

Background Data regarding the use of direct oral anticoagulants (DOACs) for the treatment
of acute pulmonary embolism (PE) are sparse. We conducted a prospective multicentre …

Direct oral anticoagulants (DOACs) have been shown to be effective and safe in preventing
pulmonary embolism recurrence. In this single-center retrospective observational study, we …

Direct oral anti-coagulants (DOACs) reduce hospital length-of-stay (LOS) in patients with
acute pulmonary embolism (PE) in clinical trials. There is a paucity of literature describing …

The clinical management of patients with acute pulmonary embolism is rapidly changing
over the years. The widening spectrum of clinical management strategies for these patients …

Objectives The safety and efficacy of direct oral anticoagulants (DOACs) in intermediate-
high risk pulmonary embolism (PE) are unknown. The aims of the present study were to …

Direct-acting oral anticoagulants (DOACs) are prescribed in the treatment of venous
thromboembolism, including pulmonary embolism (PE). Evidence is limited regarding the …

Direct oral anticoagulants (DOAC) are first line treatment for pulmonary embolism (PE).
Treatment of acute PE is traditionally hospital based and associated with high costs. The …

Background Extended oral anticoagulant (OA) use is recommended in patients with acute
pulmonary embolism (PE) who require secondary thromboprophylaxis. Nevertheless, the …

The treatment of acute venous thromboembolism (VTE) is being completely modified with
the development of direct oral anticoagulants (DOACs). Rivaroxaban, apixaban and …